Patrick G. Enright serves as Independent Director of the Company. Since 2006, Mr. Enright has served as a member of our board of directors since the closing of the Azur Merger in January 2012 and was a director of Jazz Pharmaceuticals, Inc. from 2009 until the closing of the Azur Merger. Since 2006, Mr. Enright has served as Managing Director of Longitude Capital, a venture capital firm, of which he is a founder. Prior to Longitude Capital, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund at Diaz & Altschul Capital Management. Mr. Enright began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience including senior executive positions at Valentis, Boehringer Mannheim (acquired by Roche) and Sandoz (now known as Novartis). Mr. Enright currently serves on the boards of Aimmune Therapeutics, Inc., Aptinyx Inc., CuraSen Therapeutics, Inc., Orbus Therapeutics, Inc., Rivus Pharmaceuticals, Inc. and SutroVax, Inc. Selected prior public company board memberships include Codexis, Inc., Corcept Therapeutics, Inc., Esperion Therapeutics, Inc., Horizon Pharma plc and Threshold Pharmaceuticals, Inc. Mr. Enright received a B.S. in Biological Sciences from Stanford University and an M.B.A. from the Wharton School of Business at the University of Pennsylvania. Based on his experience as a venture capital investor focused on life sciences companies and his past work in the pharmaceutical industry, Mr. Enright brings to our board of directors over 30 years of operating experience and financial expertise in the life sciences industry.
What is Patrick G. Enright's net worth?
The estimated net worth of Patrick G. Enright is at least $185.69 million as of February 6th, 2023. Mr. Enright owns 1,714,285 shares of Jazz Pharmaceuticals stock worth more than $185,691,351 as of April 24th. This net worth evaluation does not reflect any other investments that Mr. Enright may own. Learn More about Patrick G. Enright's net worth.
How do I contact Patrick G. Enright?
Has Patrick G. Enright been buying or selling shares of Jazz Pharmaceuticals?
Patrick G. Enright has not been actively trading shares of Jazz Pharmaceuticals during the past quarter. Most recently, Patrick G. Enright sold 4,974 shares of the business's stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $149.48, for a transaction totalling $743,513.52. Following the completion of the sale, the director now directly owns 19,112 shares of the company's stock, valued at $2,856,861.76. Learn More on Patrick G. Enright's trading history.
Who are Jazz Pharmaceuticals' active insiders?
Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Robert Iannone (EVP), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?
During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 10 times. They sold a total of 13,870 shares worth more than $1,827,470.63. The most recent insider tranaction occured on March, 6th when CAO Patricia Carr sold 1,936 shares worth more than $231,623.04. Insiders at Jazz Pharmaceuticals own 4.4% of the company.
Learn More about insider trades at Jazz Pharmaceuticals. Information on this page was last updated on 3/6/2024.
